Abstracts tagged "Pediatric rheumatology"

Abstract Number: 1284 • 2017 ACR/ARHP Annual Meeting
The Localized Scleroderma Quality of Life Instrument (LoSQI): Initial Validation in Pediatric Localized Scleroderma
Christina K. Zigler¹, Kaveh Ardalan², Kaila Schollaert-Fitch³, Heidi Jacobe⁴ and Kathryn S. Torok³, ¹Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: There is a current need to integrate health related quality of life (HRQoL) into outcomes for clinical trials (Chang & Reeve, 2005). For pediatric…
Abstract Number: 1285 • 2017 ACR/ARHP Annual Meeting
Extracutaneous Involvement Is Common in Juvenile Localized Scleroderma and Associated with a Higher Level of Perceived Disease Impact
Suzanne C. Li¹, Tracy Andrews², Mallory Chen³, Kathryn S. Torok⁴, Elena Pope⁵, Katie G. Stewart⁶, Gloria C. Higgins⁷, C. Egla Rabinovich⁸, Ronald M. Laxer⁹, Kathleen Haines¹⁰, Marilynn Punaro¹¹, Heidi Jacobe¹² and Kathleen O'Neil¹³, ¹Pediatrics, Joseph M Sanzari Children's Hospital, Hackensack Meridian Health, Hackensack, NJ, ²Research, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, NJ, ³Williams College, williamstown, MA, ⁴Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁵Section of Dermatology, The Hospital for Sick Children, Hospital for Sick Children, Toronto, ON, Canada, ⁶Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ⁷Pediatric Rheumatology Ohio State University, Nationwide Childrens Hospital, Columbus, OH, ⁸Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ⁹Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ¹¹Texas Scottish Rite Hospital for Children, Dallas, TX, ¹²Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ¹³Pediatric Rheumatology, RIley Hospital for Children, Indianapolis, IN
Background/Purpose: Juvenile localized scleroderma (jLS) is often associated with deep tissue and extracutaneous involvement (ECI), putting children at risk for severe morbidity such as hemiatrophy,…
Abstract Number: 1288 • 2017 ACR/ARHP Annual Meeting
Renal Disease Course in Pediatric Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis in the First 12-Months – a Pediatric Vasculitis Initiative (PedVas) Study
Kimberly Morishita¹, Audrea Chen², Cherry Mammen¹, Angelyne Rivera³ and David Cabral¹, ¹BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Medicine, University of British Columbia, Vancouver, BC, Canada, ³Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Renal disease is the most common manifestation of pediatric anti-neutrophil cycloplasmic antibody (ANCA) associated vasculitis (AAV). Renal disease course and early trajectories have not…
Abstract Number: 1728 • 2017 ACR/ARHP Annual Meeting
Interferon Gamma (IFN-γ) Subpopulations in Skin Homing T Cells of Localized Scleroderma
Claudia Macaubas¹, Emily Mirizio², Kaila Schollaert-Fitch³, Elizabeth D. Mellins⁴ and Kathryn S. Torok³, ¹Department of Pediatrics, Program in Immunology, Stanford University Med Ctr, Stanford, CA, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Dept of Pediatrics CCSR, Stanford University Med Ctr, Stanford, CA
Background/Purpose: Localized scleroderma (LS) has both inflammatory and fibrotic components contributing to its effect on the skin and underlying tissue. The understanding of the pathophysiology…
Abstract Number: 2252 • 2017 ACR/ARHP Annual Meeting
Initial Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) in Children with Juvenile Myositis
Kaveh Ardalan^1,2, David Cella³, Lauren M. Pachman⁴, Elizabeth L. Gray⁵, Julia (Jungwha) Lee⁵, Kyle Fahey^6,7, Madison Wolfe^6,7, Megan L. Curran^7,8, Mariana C. Marques^6,7 and Rowland W. Chang⁹, ¹Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁵Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁷Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Division of Rheumatology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Preventive Medicine, Medicine, and Physical Medicine & Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Juvenile myositis (JM) can worsen quality of life (QoL) via proximal weakness, rashes, and treatments side effects. QoL legacy instruments may be limited by…
Abstract Number: 2259 • 2017 ACR/ARHP Annual Meeting
Quality of Life Evaluation in New Onset Juvenile Dermatomyositis Patients from the Printo Trial
Andressa Guariento¹, Gabriella Giancane², Elena Fueri¹, Francesco Zulian³, Angelo Ravelli⁴, Bo Magnusson³, Tadej Avcin³, Fabrizia Corona³, Valeria Gerloni¹, Claudia Bracaglia¹, Rolando Cimaz¹, Antonella Meini², Silvana Martino³, Anne Pagnier¹, Michel Rodiere³, Christine Soler³, Valda Stanevicha³, Rebecca ten Cate⁵, Jelena Vojinovic³, Simona Angioloni¹, Luca Villa¹, Michele Pesce¹, Irene Gregorini¹, Chiara Pallotti¹, Alberto Martini⁶, Angela Pistorio³ and Nicola Ruperto³, ¹Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ²Pediatria II, Reumatologia - PRINTO, Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ³Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, ⁴University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁵Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common clinical pediatric idiopathic inflammatory myopathy and it may severely compromise the quality of life of affected patients.…
Abstract Number: 2294 • 2017 ACR/ARHP Annual Meeting
Utilizing the Pediatric Rheumatology Care and Outcomes Improvement Network to Assess Practice Pattern Variation in Juvenile Idiopathic Arthritis
Emily A. Smitherman¹, Janalee Taylor², Esi M. Morgan¹ and C. April Bingham³, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatrics, Penn State College of Medicine, Hershey, PA
Background/Purpose: Despite modern treatment options for patients with juvenile idiopathic arthritis (JIA), rates of clinical inactive disease (CID) remain low. The Pediatric Rheumatology Care and…
Abstract Number: 2309 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Arthritis and the Development of Comorbid Cardiovascular and Metabolic Disease in Children with Psoriasis
Cynthia K. Manos^1,2, Rui Xiao³, Timothy G. Brandon¹, Alexis Ogdie⁴ and Pamela F. Weiss^5,6, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, Philadelphia, PA, ³Department of Pediatrics, Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Department of Pediatrics, Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Relatively little is known about the epidemiology of juvenile psoriatic arthritis (PsA), including risk factors for development of PsA among children with psoriasis. It…
Abstract Number: 64 • 2017 Pediatric Rheumatology Symposium
Evaluating Levels of Activity and Health-Related Quality of Life in a Pilot Cohort of Youth Athletes with Juvenile Idiopathic Arthritis
Tommy Gerschman¹, Jordan Raugust², Julia Brooks³, Nicole Johnson¹, Nadia Luca⁴, Rebeka Stevenson¹, Heinrike Schmeling⁵, Paivi Miettunen¹ and Susanne Benseler⁴, ¹Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ²Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada, ³Pediatrics, Alberta Children's Hospital, Calgary, AB, Canada, ⁴Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁵University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: Children with JIA are increasingly being encouraged to be physically active and are participating in organized and competitive sports as youth athletes. These youth…
Abstract Number: 47 • 2017 Pediatric Rheumatology Symposium
Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study
Sarah Ringold¹, George A. Tomlinson², Pamela F. Weiss³, Laura E. Schanberg⁴, Brian M. Feldman⁵, Mary Ellen Riordan⁶, Anne C. Dennos⁷, Vincent Del Gaizo⁸, Kate Murphy⁹, Yukiko Kimura⁶ and the CARRA Registry Investigators, ¹Seattle Children's Hospital, Seattle, WA, ²Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, Duke Medical Center, Durham, NC, ⁵Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁶Hackensack University Medical Center, Hackensack, NJ, ⁷Duke Clinical Research Institute, Durham, NC, ⁸Parent Partner, Whitehouse Station, NJ, ⁹Patient Partner, San Francisco, CA
Background/Purpose: Many new effective treatments for polyarticular JIA (p-JIA) are available, but there is significant variation among pediatric rheumatologists in the timing of when biologic…
Abstract Number: 60 • 2017 Pediatric Rheumatology Symposium
Paediatric Arthritis Rehabilitation Exercise Study
Claire LeBlanc^1,2, Sophie Laniel³, Michele Geoffrion⁴, Alexandra Sirois⁵, Sofia Nene⁶, Sophie Cloutier⁷, Yun Gao⁸, Karine Toupin-April⁹, Sarah Campillo¹⁰, Gaëlle Chédeville¹¹ and Rosie Scuccimarri¹², ¹Pediatrics, Montreal Children's Hospital, Montreal, QC, Canada, ²Montreal Children's Hospital, McGill University, Montreal, QC, Canada, ³rehabilitaion medicine, co-PI, Montreal, QC, Canada, ⁴rehabilitation, co-PI, Montreal, QC, Canada, ⁵Kinesiology, Student, Montreal, QC, Canada, ⁶medicine, research student, Montreal, QC, Canada, ⁷pediatrics, research student, Montreal, QC, Canada, ⁸research student, Montreal, QC, Canada, ⁹Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ¹⁰Montreal Children's Hospital, Montreal, QC, Canada, ¹¹Rheumatology, McGill University, Montreal, QC, Canada, ¹²Division of Pediatric Rheumatology, Montreal Children's Hospital/McGill University Health Centre, Montreal, QC, Canada
JIA patients often require regular exercises to increase joint range of motion (ROM). Adherence is challenging; instruction by a physiotherapist (PT) / occupational therapist (OT)…
Abstract Number: 87 • 2016 ACR/ARHP Annual Meeting
Familiarity Vital for Telemedicine Uptake Among Parents of Pediatric Rheumatology Patients
Danielle R. Bullock¹, Richard K. Vehe², Lei Zhang³ and Colleen K. Correll¹, ¹Pediatrics, University of Minnesota, Minneapolis, MN, ²Department of Pediatrics, University of Minnesota, Minneapolis, MN, ³University of Minnesota, Minneapolis, MN
Background/Purpose: The United States pediatric rheumatology (PR) workforce is committed to a mission of providing children access to PR care. With a limited number and…
Abstract Number: 112 • 2016 ACR/ARHP Annual Meeting
Leveraging a Learning Network to Implement and Standardize Self-Management Support into Care Delivery: Experience of Pediatric Rheumatology Care and Outcomes Improvement Network
Janalee Taylor¹, Avani Modi², Kristin Loiselle², Julie Gomez³, Karla B. Jones⁴, Sheetal S. Vora⁵, Julia Harris⁶, Beth Gottlieb⁷, Lisa Robbins⁸, Tzielan Lee⁹, Kristi Whitney-Mahoney¹⁰, Murray Passo¹¹, Melanie Kohlheim¹², Laura Curtis¹², Anjie Vago¹³, Kerry Ferraro¹², Kate Trevey¹², Jennifer Gil¹², Laura Bouslaugh¹², Angela Young¹², Nancy Griffin¹⁴, Anne Paul¹⁵, Carole M. Lannon¹⁴ and Esi Morgan¹⁶, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Center for Treatment Adherence and Self-Management, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, Nationwide Children's, Columbus, OH, ⁵Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁶Children's Mercy Kansas City, Kansas City, MO, ⁷Pediatrics, Cohen Children's Medical Center, Lake Success, NY, ⁸Penn State Hershey Children's Hospital, Hershey, PA, ⁹Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ¹⁰The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹²Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ¹³Pediatric Rheumatology Care and Outcomes Improvement Network, cincinnati, OH, ¹⁴James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Disease outcomes can depend, to a large extent, on one’s ability to manage their condition effectively. For children with JIA this means managing oral,…
Abstract Number: 392 • 2016 ACR/ARHP Annual Meeting
Safety and Clinical Response of Weekly Adalimumab in the Treatment of Juvenile Idiopathic Arthritis, Pediatric Chronic Uveitis and Other Childhood Rheumatic Diseases
Colleen K. Correll¹, Danielle R. Bullock¹, Rachel Cafferty¹ and Richard K Vehe², ¹Pediatrics, University of Minnesota, Minneapolis, MN, ²University of Minnesota Masonic Children’s Hospital, Minneapolis, MN
Background/Purpose: Every other week adalimumab is used to treat juvenile idiopathic arthritis (JIA) and other pediatric rheumatic diseases. It is common for pediatric rheumatologists to…
Abstract Number: 395 • 2016 ACR/ARHP Annual Meeting
The Influence of Early Achievement of “Clinically Inactive Disease” or “Minimal Disease Activity” on Long-Term Disability Outcomes in JIA
Stephanie J.W.Shoop^1,2, Suzanne M.M. Verstappen³, Janet E. McDonagh⁴, Wendy Thomson^5,6, Kimme L. Hyrich^3,7 and CAPS, ¹Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ²The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Different definitions of clinically inactive disease (CID) for JIA have recently been shown to identify different groups of children. It is unclear whether long-term…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].